Equities

Xencor Inc

Xencor Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)21.20
  • Today's Change0.35 / 1.68%
  • Shares traded433.31k
  • 1 Year change+0.47%
  • Beta0.6571
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy4
Outperform6
Hold1
Sell1
Strong Sell0

Share price forecast in USD

The 10 analysts offering 12 month price targets for Xencor Inc have a median target of 32.00, with a high estimate of 59.00 and a low estimate of 20.00. The median estimate represents a 50.94% increase from the last price of 21.20.
High178.3%59.00
Med50.9%32.00
Low-5.7%20.00

Earnings history & estimates in USD

On Aug 05, 2024, Xencor Inc reported 2nd quarter 2024 losses of -1.07 per share.
The next earnings announcement is expected on Nov 05, 2024.
Average growth rate-60.02%
Xencor Inc reported annual 2023 losses of -2.08 per share on Feb 27, 2024.
Average growth rate-123.66%
More ▼

Revenue history & estimates in USD

Xencor, Inc. had 2nd quarter 2024 revenues of 16.96m. This bettered the 15.83m consensus of the 9 analysts covering the company. This was 10.56% below the prior year's 2nd quarter results.
Average growth rate-8.35%
Xencor, Inc. had revenues for the full year 2023 of 168.34m. This was 2.28% above the prior year's results.
Average growth rate+16.16%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.